DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Loracarbef versus cefaclor in the treatment of urinary tract infections in women.

Author(s): Iravani A

Affiliation(s): Department of Pediatrics, College of Medicine, University of Florida, Gainesville 32610-0296.

Publication date & source: 1991-04, Antimicrob Agents Chemother., 35(4):750-2.

Publication type: Clinical Trial; Randomized Controlled Trial

In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017